The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.
about
Current and emerging treatment strategies for Duchenne muscular dystrophyAssessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging optionsAnimal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy¹³C NMR metabolomics: applications at natural abundanceThe burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence reviewThe 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes.Dystrophic Cardiomyopathy-Potential Role of Calcium in Pathogenesis, Treatment and Novel TherapiesCooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophyThe cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing anThe 6-Minute Walk Test and Person-Reported Outcomes in Boys with Duchenne Muscular Dystrophy and Typically Developing Controls: Longitudinal Comparisons and Clinically-Meaningful Changes Over One Year.Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History StudyLarge-scale serum protein biomarker discovery in Duchenne muscular dystrophyLongitudinal Evaluation of Muscle Composition Using Magnetic Resonance in 4 Boys With Duchenne Muscular Dystrophy: Case Series.Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study.Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular DystrophyNon-invasive evaluation of muscle disease in the canine model of Duchenne muscular dystrophy by electrical impedance myography.The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study.The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter studyPrednisolone improves walking in Japanese Duchenne muscular dystrophy patientsAssociation Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy.Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy.Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy.Interleukin 1 Receptor-Like 1 Protein (ST2) is a Potential Biomarker for Cardiomyopathy in Duchenne Muscular Dystrophy.Pulmonary Endpoints in Duchenne Muscular Dystrophy. A Workshop Summary.Mass spectrometry-based protein analysis to unravel the tissue pathophysiology in Duchenne muscular dystrophy.Sleep Disordered Breathing in Duchenne Muscular Dystrophy.Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.Functional changes in Becker muscular dystrophy: implications for clinical trials in dystrophinopathiesEfficacy of Idebenone to Preserve Respiratory Function above Clinically Meaningful Thresholds for Forced Vital Capacity (FVC) in Patients with Duchenne Muscular Dystrophy.Seeking a better landscape for therapy development in neuromuscular disorders.Clinical trial readiness in non-ambulatory boys and men with duchenne muscular dystrophy: MDA-DMD network follow-up.An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy.Evaluation of cardiac functions in children with Duchenne Muscular Dystrophy: A prospective case-control study.Semi-Automated Analysis of Diaphragmatic Motion with Dynamic Magnetic Resonance Imaging in Healthy Controls and Non-Ambulant Subjects with Duchenne Muscular Dystrophy.Quality of life of patients with Duchenne muscular dystrophy: from adolescence to young men.SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy.Changes in Muscle Metabolism are Associated with Phenotypic Variability in Golden Retriever Muscular Dystrophy.
P2860
Q26741535-DF9B8FFC-7959-4A69-A60A-3111E8E17E0CQ26785627-7ED3B388-07C6-4024-B8A2-EF754A6C3BA6Q28084979-C6EA3BB6-A23A-48B7-A1D2-0ACAC9EF678FQ29169154-CADC76C7-1D49-4E61-B59B-649DFB6B7291Q30234649-72FEFEAB-0539-456D-8152-F788DBFFE644Q30557216-B37AD7EB-27C0-496C-A58F-30F462CF451EQ30856806-D07FBA07-C888-462C-869E-9198EFEC1933Q33608478-6DFF2F10-4707-4BBA-9D1A-4851A1FCC967Q33844719-BA8D9844-CC38-4030-AD99-234EE1A3FC38Q33919009-54DF6CBD-5892-4E98-AA1F-2453BA76BBB5Q34836557-6511A4DA-C7A3-4AB9-ABCD-1C759D5AF555Q35495274-5772EBD4-4E0D-4DA0-9D11-8109479334AAQ35740280-5FEDAAC5-1EE0-42AC-B25D-19A7A6B9DA56Q35837371-59BA56BB-96D0-4DDC-A593-7384F4329011Q35991086-B2DFC17F-D7C8-4CB3-B677-D289576979A8Q36155677-4B4A27B5-4533-4F3E-9895-4930762C2C20Q36287980-21791843-7950-4585-8285-AECCCFA9E3DCQ36322048-D2ADE278-D7FE-4002-8AD9-FA9658657B2DQ36577433-45AD41BD-E6F9-4B14-A1DD-1BF859ECA02FQ37158951-BE822759-646A-4F92-803F-6520D89CD725Q37298079-96D9A3EC-4090-4831-8D17-162D8EE47233Q37349765-21368314-DFBD-4231-8B4D-BBF20F8BF423Q37396900-5A016042-6239-45DA-AE9A-3E78B512F9A5Q38125499-B779FE2B-FB9A-49FD-B0F0-95BCE534B6ABQ38302852-EACC44F5-B9A5-4ADF-85E8-FD6827675378Q38640186-9C6A4B95-1A0E-4DB4-9EE4-45B10C3F0116Q38715671-9880F711-A58D-4C48-B681-55ACA74A8AECQ38717697-5E70CB83-21C8-42E5-8FF0-5FA5D70AE04BQ39233391-FB733EA6-5D85-4D35-9070-E418F9BF1FECQ40316979-1726BFA8-D166-4893-931B-BCDC6A51C6DBQ40991213-A34930AF-B1A4-42F2-99B0-9578EE1D0055Q42363355-57F17EA2-8C70-4D30-997E-ECF792AB311FQ42688781-E45D30C2-1EB5-4DCD-B5C1-0A22082DBD09Q45883669-F4285867-A428-43C1-93D7-100A61B7510BQ47607031-471B0B1A-0526-4ABE-84C5-E8BC449B0F7DQ49164127-BA42FCE8-4A10-4302-BF32-D927BA14CC45Q49521240-92168464-D83C-485E-9F84-885E2560CE04Q50201365-6316A74A-D6F3-45B9-AC4C-10D71DE5D851Q51065898-965A5FDB-4BB1-431D-8001-D3C1CC61B2A1Q54988224-9738EE6D-FCD9-4289-B326-3DD14A3FCBE6
P2860
The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The cooperative international ...... protocol and the methods used.
@ast
The cooperative international ...... protocol and the methods used.
@en
The cooperative international ...... protocol and the methods used.
@nl
type
label
The cooperative international ...... protocol and the methods used.
@ast
The cooperative international ...... protocol and the methods used.
@en
The cooperative international ...... protocol and the methods used.
@nl
prefLabel
The cooperative international ...... protocol and the methods used.
@ast
The cooperative international ...... protocol and the methods used.
@en
The cooperative international ...... protocol and the methods used.
@nl
P2093
P2860
P356
P1433
P1476
The cooperative international ...... protocol and the methods used.
@en
P2093
Adrienne Arrieta
Avital Cnaan
Cinrg Investigators
Diana M Escolar
Eric P Hoffman
Erik K Henricson
Julaine M Florence
Paula R Clemens
R Ted Abresch
P2860
P356
10.1002/MUS.23807
P577
2013-05-16T00:00:00Z